MKI67 and breast cancer: However, their advantages over other biomolecules, such as proteins and mRNAs, have been demonstrated [40], as is the case of GATA3-AS1, which predicts neoadjuvant chemotherapy resistance in luminal B-like breast cancer patients with a sensitivity of 92% and specificity of 75% (p-value = 0.0001) [17] compared to Ki-67, a clinical biomarker for neoadjuvant chemotherapy response prediction in breast cancer (sensitivity: 95.7%, specificity: 54.3%, p-value  =  0.002) [103].